Advanced Search
Display options
Filter resources
Text Availability
Article type
Publication date
Species
Language
Sex
Age
Showing 1 to 12 of 79 entries
Sorted by: Best Match Show Resources per page
The glutamatergic aspects of schizophrenia molecular pathophysiology: role of the postsynaptic density, and implications for treatment.

Current neuropharmacology

Iasevoli F, Tomasetti C, Buonaguro EF, de Bartolomeis A.
PMID: 24851087
Curr Neuropharmacol. 2014 May;12(3):219-38. doi: 10.2174/1570159X12666140324183406.

Schizophrenia is one of the most debilitating psychiatric diseases with a lifetime prevalence of approximately 1%. Although the specific molecular underpinnings of schizophrenia are still unknown, evidence has long linked its pathophysiology to postsynaptic abnormalities. The postsynaptic density (PSD)...

Cite
Iasevoli F, Tomasetti C, Buonaguro EF, et al. The glutamatergic aspects of schizophrenia molecular pathophysiology: role of the postsynaptic density, and implications for treatment. Curr Neuropharmacol. 2014;12(3):219-38doi: 10.2174/1570159X12666140324183406.
Iasevoli, F., Tomasetti, C., Buonaguro, E. F., & de Bartolomeis, A. (2014). The glutamatergic aspects of schizophrenia molecular pathophysiology: role of the postsynaptic density, and implications for treatment. Current neuropharmacology, 12(3), 219-38. https://doi.org/10.2174/1570159X12666140324183406
Iasevoli, Felice, et al. "The glutamatergic aspects of schizophrenia molecular pathophysiology: role of the postsynaptic density, and implications for treatment." Current neuropharmacology vol. 12,3 (2014): 219-38. doi: https://doi.org/10.2174/1570159X12666140324183406
Iasevoli F, Tomasetti C, Buonaguro EF, de Bartolomeis A. The glutamatergic aspects of schizophrenia molecular pathophysiology: role of the postsynaptic density, and implications for treatment. Curr Neuropharmacol. 2014 May;12(3):219-38. doi: 10.2174/1570159X12666140324183406. PMID: 24851087; PMCID: PMC4023453.
Copy Download .nbib Format: NLM
Systems Biology Approach for Cancer Vaccine Development and Evaluation.

Vaccines

Circelli L, Petrizzo A, Tagliamonte M, Tornesello ML, Buonaguro FM, Buonaguro L.
PMID: 26350594
Vaccines (Basel). 2015 Jul 14;3(3):544-55. doi: 10.3390/vaccines3030544.

Therapeutic cancer vaccines do not hold promise yet as an effective anti-cancer treatment. Lack of efficacy or poor clinical outcomes are due to several antigenic and immunological aspects that need to be addressed in order to reverse such trends...

Cite
Circelli L, Petrizzo A, Tagliamonte M, et al. Systems Biology Approach for Cancer Vaccine Development and Evaluation. Vaccines (Basel). 2015;3(3):544-55doi: 10.3390/vaccines3030544.
Circelli, L., Petrizzo, A., Tagliamonte, M., Tornesello, M. L., Buonaguro, F. M., & Buonaguro, L. (2015). Systems Biology Approach for Cancer Vaccine Development and Evaluation. Vaccines, 3(3), 544-55. https://doi.org/10.3390/vaccines3030544
Circelli, Luisa, et al. "Systems Biology Approach for Cancer Vaccine Development and Evaluation." Vaccines vol. 3,3 (2015): 544-55. doi: https://doi.org/10.3390/vaccines3030544
Circelli L, Petrizzo A, Tagliamonte M, Tornesello ML, Buonaguro FM, Buonaguro L. Systems Biology Approach for Cancer Vaccine Development and Evaluation. Vaccines (Basel). 2015 Jul 14;3(3):544-55. doi: 10.3390/vaccines3030544. PMID: 26350594; PMCID: PMC4586466.
Copy Download .nbib Format: NLM
Guidelines of the Italian Society for Virology on HPV testing and vaccination for cervical cancer prevention.

Infectious agents and cancer

Barzon L, Giorgi C, Buonaguro FM, Palù G.
PMID: 19087272
Infect Agent Cancer. 2008 Dec 16;3:14. doi: 10.1186/1750-9378-3-14.

OBJECTIVE: To provide guidelines for health-care providers on strategies for cervical cancer prevention based on HPV testing and anti-HPV vaccination.OUTCOMES: Overall efficacy of different preventive strategies, assessing reduction in the incidence of invasive cervical cancer and precancerous lesions.EVIDENCE: Medline...

Cite
Barzon L, Giorgi C, Buonaguro FM, et al. Guidelines of the Italian Society for Virology on HPV testing and vaccination for cervical cancer prevention. Infect Agent Cancer. 2008;3:14doi: 10.1186/1750-9378-3-14.
Barzon, L., Giorgi, C., Buonaguro, F. M., Palù, G. (2008). Guidelines of the Italian Society for Virology on HPV testing and vaccination for cervical cancer prevention. Infectious agents and cancer, 314. https://doi.org/10.1186/1750-9378-3-14
Barzon, Luisa, et al. "Guidelines of the Italian Society for Virology on HPV testing and vaccination for cervical cancer prevention." Infectious agents and cancer vol. 3 (2008): 14. doi: https://doi.org/10.1186/1750-9378-3-14
Barzon L, Giorgi C, Buonaguro FM, Palù G. Guidelines of the Italian Society for Virology on HPV testing and vaccination for cervical cancer prevention. Infect Agent Cancer. 2008 Dec 16;3:14. doi: 10.1186/1750-9378-3-14. PMID: 19087272; PMCID: PMC2628336.
Copy Download .nbib Format: NLM
TP53 and MDM2 gene polymorphisms and risk of hepatocellular carcinoma among Italian patients.

Infectious agents and cancer

Di Vuolo V, Buonaguro L, Izzo F, Losito S, Botti G, Buonaguro FM, Tornesello ML.
PMID: 21843334
Infect Agent Cancer. 2011 Aug 15;6:13. doi: 10.1186/1750-9378-6-13.

BACKGROUND: Single-nucleotide polymorphisms within TP53 gene (codon 72 exon 4, rs1042522, encoding either arginine or proline) and MDM2 promoter (SNP309; rs2279744), have been independently associated with increased risk of several cancer types. Few studies have analysed the role of...

Cite
Di Vuolo V, Buonaguro L, Izzo F, et al. TP53 and MDM2 gene polymorphisms and risk of hepatocellular carcinoma among Italian patients. Infect Agent Cancer. 2011;6:13doi: 10.1186/1750-9378-6-13.
Di Vuolo, V., Buonaguro, L., Izzo, F., Losito, S., Botti, G., Buonaguro, F. M., & Tornesello, M. L. (2011). TP53 and MDM2 gene polymorphisms and risk of hepatocellular carcinoma among Italian patients. Infectious agents and cancer, 613. https://doi.org/10.1186/1750-9378-6-13
Di Vuolo, Valeria, et al. "TP53 and MDM2 gene polymorphisms and risk of hepatocellular carcinoma among Italian patients." Infectious agents and cancer vol. 6 (2011): 13. doi: https://doi.org/10.1186/1750-9378-6-13
Di Vuolo V, Buonaguro L, Izzo F, Losito S, Botti G, Buonaguro FM, Tornesello ML. TP53 and MDM2 gene polymorphisms and risk of hepatocellular carcinoma among Italian patients. Infect Agent Cancer. 2011 Aug 15;6:13. doi: 10.1186/1750-9378-6-13. PMID: 21843334; PMCID: PMC3170208.
Copy Download .nbib Format: NLM
Efficacy and clinical determinants of antipsychotic polypharmacy in psychotic patients experiencing an acute relapse and admitted to hospital stay: results from a cross-sectional and a subsequent longitudinal pilot study.

ISRN pharmacology

Iasevoli F, Buonaguro EF, Marconi M, Di Giovambattista E, Rapagnani MP, De Berardis D, Martinotti G, Mazza M, Balletta R, Serroni N, Di Giannantonio M, de Bartolomeis A, Valchera A.
PMID: 24592333
ISRN Pharmacol. 2014 Jan 27;2014:762127. doi: 10.1155/2014/762127. eCollection 2014.

Background. Antipsychotic polypharmacy is used in several psychiatric disorders, despite poor evidence existing to support this practice. Aim. We evaluated whether psychotic patients in acute relapse exposed to antipsychotic polypharmacy (AP + AP) showed different demographic, clinical, or psychopathological...

Cite
Iasevoli F, Buonaguro EF, Marconi M, et al. Efficacy and clinical determinants of antipsychotic polypharmacy in psychotic patients experiencing an acute relapse and admitted to hospital stay: results from a cross-sectional and a subsequent longitudinal pilot study. ISRN Pharmacol. 2014;2014:762127doi: 10.1155/2014/762127.
Iasevoli, F., Buonaguro, E. F., Marconi, M., Di Giovambattista, E., Rapagnani, M. P., De Berardis, D., Martinotti, G., Mazza, M., Balletta, R., Serroni, N., Di Giannantonio, M., de Bartolomeis, A., & Valchera, A. (2014). Efficacy and clinical determinants of antipsychotic polypharmacy in psychotic patients experiencing an acute relapse and admitted to hospital stay: results from a cross-sectional and a subsequent longitudinal pilot study. ISRN pharmacology, 2014762127. https://doi.org/10.1155/2014/762127
Iasevoli, Felice, et al. "Efficacy and clinical determinants of antipsychotic polypharmacy in psychotic patients experiencing an acute relapse and admitted to hospital stay: results from a cross-sectional and a subsequent longitudinal pilot study." ISRN pharmacology vol. 2014 (2014): 762127. doi: https://doi.org/10.1155/2014/762127
Iasevoli F, Buonaguro EF, Marconi M, Di Giovambattista E, Rapagnani MP, De Berardis D, Martinotti G, Mazza M, Balletta R, Serroni N, Di Giannantonio M, de Bartolomeis A, Valchera A. Efficacy and clinical determinants of antipsychotic polypharmacy in psychotic patients experiencing an acute relapse and admitted to hospital stay: results from a cross-sectional and a subsequent longitudinal pilot study. ISRN Pharmacol. 2014 Jan 27;2014:762127. doi: 10.1155/2014/762127. eCollection 2014. PMID: 24592333; PMCID: PMC3921985.
Copy Download .nbib Format: NLM
Cellular prognostic markers in hepatitis-related hepatocellular carcinoma.

Infectious agents and cancer

Petrizzo A, Mauriello A, Tornesello ML, Buonaguro FM, Tagliamonte M, Buonaguro L.
PMID: 29599818
Infect Agent Cancer. 2018 Mar 27;13:10. doi: 10.1186/s13027-018-0183-8. eCollection 2018.

Hepatocellular carcinoma (HCC) is the most common primary liver malignancy and accounts for about 6% of all new cancers diagnosed worldwide. Moreover, it is the third and the fifth leading cause of death from cancer in men and women,...

Cite
Petrizzo A, Mauriello A, Tornesello ML, et al. Cellular prognostic markers in hepatitis-related hepatocellular carcinoma. Infect Agent Cancer. 2018;13:10doi: 10.1186/s13027-018-0183-8.
Petrizzo, A., Mauriello, A., Tornesello, M. L., Buonaguro, F. M., Tagliamonte, M., & Buonaguro, L. (2018). Cellular prognostic markers in hepatitis-related hepatocellular carcinoma. Infectious agents and cancer, 1310. https://doi.org/10.1186/s13027-018-0183-8
Petrizzo, A, et al. "Cellular prognostic markers in hepatitis-related hepatocellular carcinoma." Infectious agents and cancer vol. 13 (2018): 10. doi: https://doi.org/10.1186/s13027-018-0183-8
Petrizzo A, Mauriello A, Tornesello ML, Buonaguro FM, Tagliamonte M, Buonaguro L. Cellular prognostic markers in hepatitis-related hepatocellular carcinoma. Infect Agent Cancer. 2018 Mar 27;13:10. doi: 10.1186/s13027-018-0183-8. eCollection 2018. PMID: 29599818; PMCID: PMC5870199.
Copy Download .nbib Format: NLM
Effect of electrochemotherapy on human herpesvirus 8 kinetics in classic Kaposi sarcoma.

Infectious agents and cancer

Starita N, Di Monta G, Cerasuolo A, Marone U, Anniciello AM, Botti G, Buonaguro L, Buonaguro FM, Tornesello ML.
PMID: 28649271
Infect Agent Cancer. 2017 Jun 19;12:35. doi: 10.1186/s13027-017-0147-4. eCollection 2017.

BACKGROUND: Electrochemotherapy (ECT) has shown to be an effective treatment for cutaneous and subcutaneous Kaposi sarcoma (KS) lesions. However, no study has investigated the impact of ECT treatment on the kinetics of human herpesvirus type 8 (HHV8), which is...

Cite
Starita N, Di Monta G, Cerasuolo A, et al. Effect of electrochemotherapy on human herpesvirus 8 kinetics in classic Kaposi sarcoma. Infect Agent Cancer. 2017;12:35doi: 10.1186/s13027-017-0147-4.
Starita, N., Di Monta, G., Cerasuolo, A., Marone, U., Anniciello, A. M., Botti, G., Buonaguro, L., Buonaguro, F. M., & Tornesello, M. L. (2017). Effect of electrochemotherapy on human herpesvirus 8 kinetics in classic Kaposi sarcoma. Infectious agents and cancer, 1235. https://doi.org/10.1186/s13027-017-0147-4
Starita, Noemy, et al. "Effect of electrochemotherapy on human herpesvirus 8 kinetics in classic Kaposi sarcoma." Infectious agents and cancer vol. 12 (2017): 35. doi: https://doi.org/10.1186/s13027-017-0147-4
Starita N, Di Monta G, Cerasuolo A, Marone U, Anniciello AM, Botti G, Buonaguro L, Buonaguro FM, Tornesello ML. Effect of electrochemotherapy on human herpesvirus 8 kinetics in classic Kaposi sarcoma. Infect Agent Cancer. 2017 Jun 19;12:35. doi: 10.1186/s13027-017-0147-4. eCollection 2017. PMID: 28649271; PMCID: PMC5477158.
Copy Download .nbib Format: NLM
Human Oncoviruses and p53 Tumor Suppressor Pathway Deregulation at the Origin of Human Cancers.

Cancers

Tornesello ML, Annunziata C, Tornesello AL, Buonaguro L, Buonaguro FM.
PMID: 29932446
Cancers (Basel). 2018 Jun 22;10(7). doi: 10.3390/cancers10070213.

Viral oncogenesis is a multistep process largely depending on the complex interplay between viruses and host factors. The oncoviruses are capable of subverting the cell signaling machinery and metabolic pathways and exploit them for infection, replication, and persistence. Several...

Cite
Tornesello ML, Annunziata C, Tornesello AL, et al. Human Oncoviruses and p53 Tumor Suppressor Pathway Deregulation at the Origin of Human Cancers. Cancers (Basel). 2018;10(7)doi: 10.3390/cancers10070213.
Tornesello, M. L., Annunziata, C., Tornesello, A. L., Buonaguro, L., & Buonaguro, F. M. (2018). Human Oncoviruses and p53 Tumor Suppressor Pathway Deregulation at the Origin of Human Cancers. Cancers, 10(7), . https://doi.org/10.3390/cancers10070213
Tornesello, Maria Lina, et al. "Human Oncoviruses and p53 Tumor Suppressor Pathway Deregulation at the Origin of Human Cancers." Cancers vol. 10,7 (2018). doi: https://doi.org/10.3390/cancers10070213
Tornesello ML, Annunziata C, Tornesello AL, Buonaguro L, Buonaguro FM. Human Oncoviruses and p53 Tumor Suppressor Pathway Deregulation at the Origin of Human Cancers. Cancers (Basel). 2018 Jun 22;10(7). doi: 10.3390/cancers10070213. PMID: 29932446; PMCID: PMC6071257.
Copy Download .nbib Format: NLM
Novel Molecular Targets for Hepatocellular Carcinoma.

Cancers

Cavalluzzo B, Mauriello A, Ragone C, Manolio C, Tornesello ML, Buonaguro FM, Tvingsholm SA, Hadrup SR, Tagliamonte M, Buonaguro L.
PMID: 35008303
Cancers (Basel). 2021 Dec 28;14(1). doi: 10.3390/cancers14010140.

Hepatocellular carcinoma (HCC) is the third leading cause of death from cancer globally. Indeed, only a few treatments are available, most of which are effective only for the early stages of the disease. Therefore, there is an urgent needing...

Cite
Cavalluzzo B, Mauriello A, Ragone C, et al. Novel Molecular Targets for Hepatocellular Carcinoma. Cancers (Basel). 2021;14(1)doi: 10.3390/cancers14010140.
Cavalluzzo, B., Mauriello, A., Ragone, C., Manolio, C., Tornesello, M. L., Buonaguro, F. M., Tvingsholm, S. A., Hadrup, S. R., Tagliamonte, M., & Buonaguro, L. (2021). Novel Molecular Targets for Hepatocellular Carcinoma. Cancers, 14(1), . https://doi.org/10.3390/cancers14010140
Cavalluzzo, Beatrice, et al. "Novel Molecular Targets for Hepatocellular Carcinoma." Cancers vol. 14,1 (2021). doi: https://doi.org/10.3390/cancers14010140
Cavalluzzo B, Mauriello A, Ragone C, Manolio C, Tornesello ML, Buonaguro FM, Tvingsholm SA, Hadrup SR, Tagliamonte M, Buonaguro L. Novel Molecular Targets for Hepatocellular Carcinoma. Cancers (Basel). 2021 Dec 28;14(1). doi: 10.3390/cancers14010140. PMID: 35008303.
Copy Download .nbib Format: NLM
Gene Signature for Sorafenib Susceptibility in Hepatocellular Carcinoma: Different Approach with a Predictive Biomarker.

Liver cancer

Kim CM, Hwang S, Keam B, Yu YS, Kim JH, Kim DS, Bae SH, Kim GD, Lee JK, Seo YB, Nam SW, Kang KJ, Buonaguro L, Park JY, Kim YS, Wang HJ.
PMID: 32399432
Liver Cancer. 2020 Apr;9(2):182-192. doi: 10.1159/000504548. Epub 2020 Feb 18.

BACKGROUND/AIM: Uniform treatment of hepatocellular carcinoma (HCC) with molecular targeted drugs (e.g., sorafenib) results in a poor overall tumor response when tumor subtyping is absent. Patient stratification based on actionable gene expression is a method that can potentially improve...

Cite
Kim CM, Hwang S, Keam B, et al. Gene Signature for Sorafenib Susceptibility in Hepatocellular Carcinoma: Different Approach with a Predictive Biomarker. Liver Cancer. 2020;9(2):182-192doi: 10.1159/000504548.
Kim, C. M., Hwang, S., Keam, B., Yu, Y. S., Kim, J. H., Kim, D. S., Bae, S. H., Kim, G. D., Lee, J. K., Seo, Y. B., Nam, S. W., Kang, K. J., Buonaguro, L., Park, J. Y., Kim, Y. S., & Wang, H. J. (2020). Gene Signature for Sorafenib Susceptibility in Hepatocellular Carcinoma: Different Approach with a Predictive Biomarker. Liver cancer, 9(2), 182-192. https://doi.org/10.1159/000504548
Kim, Chang Min, et al. "Gene Signature for Sorafenib Susceptibility in Hepatocellular Carcinoma: Different Approach with a Predictive Biomarker." Liver cancer vol. 9,2 (2020): 182-192. doi: https://doi.org/10.1159/000504548
Kim CM, Hwang S, Keam B, Yu YS, Kim JH, Kim DS, Bae SH, Kim GD, Lee JK, Seo YB, Nam SW, Kang KJ, Buonaguro L, Park JY, Kim YS, Wang HJ. Gene Signature for Sorafenib Susceptibility in Hepatocellular Carcinoma: Different Approach with a Predictive Biomarker. Liver Cancer. 2020 Apr;9(2):182-192. doi: 10.1159/000504548. Epub 2020 Feb 18. PMID: 32399432; PMCID: PMC7206603.
Copy Download .nbib Format: NLM
Genetic instability and anti-HPV immune response as drivers of infertility associated with HPV infection.

Infectious agents and cancer

Isaguliants M, Krasnyak S, Smirnova O, Colonna V, Apolikhin O, Buonaguro FM.
PMID: 33971936
Infect Agent Cancer. 2021 May 10;16(1):29. doi: 10.1186/s13027-021-00368-1.

Human papillomavirus (HPV) is a sexually transmitted infection common among men and women of reproductive age worldwide. HPV viruses are associated with epithelial lesions and cancers. HPV infections have been shown to be significantly associated with many adverse effects...

Cite
Isaguliants M, Krasnyak S, Smirnova O, et al. Genetic instability and anti-HPV immune response as drivers of infertility associated with HPV infection. Infect Agent Cancer. 2021;16(1):29doi: 10.1186/s13027-021-00368-1.
Isaguliants, M., Krasnyak, S., Smirnova, O., Colonna, V., Apolikhin, O., & Buonaguro, F. M. (2021). Genetic instability and anti-HPV immune response as drivers of infertility associated with HPV infection. Infectious agents and cancer, 16(1), 29. https://doi.org/10.1186/s13027-021-00368-1
Isaguliants, Maria, et al. "Genetic instability and anti-HPV immune response as drivers of infertility associated with HPV infection." Infectious agents and cancer vol. 16,1 (2021): 29. doi: https://doi.org/10.1186/s13027-021-00368-1
Isaguliants M, Krasnyak S, Smirnova O, Colonna V, Apolikhin O, Buonaguro FM. Genetic instability and anti-HPV immune response as drivers of infertility associated with HPV infection. Infect Agent Cancer. 2021 May 10;16(1):29. doi: 10.1186/s13027-021-00368-1. PMID: 33971936; PMCID: PMC8111735.
Copy Download .nbib Format: NLM
Induction of Rosette-to-Lumen stage embryoids using reprogramming paradigms in ESCs.

Nature communications

Langkabel J, Horne A, Bonaguro L, Holsten L, Hesse T, Knaus A, Riedel Y, Becker M, Händler K, Elmzzahi T, Bassler K, Reusch N, Yeghiazarian LH, Pecht T, Saglam A, Ulas T, Aschenbrenner AC, Kaiser F, Kubaczka C, Schultze JL, Schorle H.
PMID: 34916498
Nat Commun. 2021 Dec 16;12(1):7322. doi: 10.1038/s41467-021-27586-w.

Blastocyst-derived stem cell lines were shown to self-organize into embryo-like structures in 3D cell culture environments. Here, we provide evidence that embryo-like structures can be generated solely based on transcription factor-mediated reprogramming of embryonic stem cells in a simple...

Cite
Langkabel J, Horne A, Bonaguro L, et al. Induction of Rosette-to-Lumen stage embryoids using reprogramming paradigms in ESCs. Nat Commun. 2021;12(1):7322doi: 10.1038/s41467-021-27586-w.
Langkabel, J., Horne, A., Bonaguro, L., Holsten, L., Hesse, T., Knaus, A., Riedel, Y., Becker, M., Händler, K., Elmzzahi, T., Bassler, K., Reusch, N., Yeghiazarian, L. H., Pecht, T., Saglam, A., Ulas, T., Aschenbrenner, A. C., Kaiser, F., Kubaczka, C., Schultze, J. L., & Schorle, H. (2021). Induction of Rosette-to-Lumen stage embryoids using reprogramming paradigms in ESCs. Nature communications, 12(1), 7322. https://doi.org/10.1038/s41467-021-27586-w
Langkabel, Jan, et al. "Induction of Rosette-to-Lumen stage embryoids using reprogramming paradigms in ESCs." Nature communications vol. 12,1 (2021): 7322. doi: https://doi.org/10.1038/s41467-021-27586-w
Langkabel J, Horne A, Bonaguro L, Holsten L, Hesse T, Knaus A, Riedel Y, Becker M, Händler K, Elmzzahi T, Bassler K, Reusch N, Yeghiazarian LH, Pecht T, Saglam A, Ulas T, Aschenbrenner AC, Kaiser F, Kubaczka C, Schultze JL, Schorle H. Induction of Rosette-to-Lumen stage embryoids using reprogramming paradigms in ESCs. Nat Commun. 2021 Dec 16;12(1):7322. doi: 10.1038/s41467-021-27586-w. PMID: 34916498; PMCID: PMC8677818.
Copy Download .nbib Format: NLM
Showing 1 to 12 of 79 entries